

## DAFTAR PUSTAKA

- Achmad Rudijanto, Agus Yuwono, Alwi Shahab, Asman Manaf, Bowo Pramono, D.L., *et al.*, 2015. Konsensus Pengendalian dan Pencegahan Diabetes Melitus Tipe 2 di Indonesia 2015, *Perkeni*.
- Bendary A., Tawfik W., Mahros M., Salem M., 2017, Fibrinolytic therapy in patients with ST-segment elevation myocardial infarction: Accelerated versus standard Streptokinase infusion regimen, *J Cardiovasc Thorac Res*, 9(4),p209 - p214.
- Boersma E, Maas AC, Deckers JW, Simoons ML, 1996, Early thrombolytic treatment in acute myocardial infarction: reappraisal of the golden hour. *The Lancet*; 348: 771-775
- Chowdhury, M.A.R., Hossain, A.K.M.M., Dey, S.R,2008, A comparative study on the effect of streptokinase between diabetic and non-diabetic myocardial infarction patients. *Bangladesh J Pharmacol*, 2(3), pp.1-7.
- Fleiss, J., Levin, B. and Paik, M., 2004, *Statistical Methods for Rates and Proportions*, Third Edition, Statistical Methods for Rates and Proportions.
- Gauer RL. dan Braun MM.,2012, Thrombocytopenia, *Am Fam Physician*, 85(6), p612-622.
- Grines, C.L., Topol, E.J., Neill, W.W.O., Califf, R.M., 1995, Effect Cigarette Smoking on Outcome After Thrombolytic Therapy for Myocardial Infarction. *Circulation*, 91, pp.298-303.
- Hamid S, Kundal V, Mahajan N, Singh P., 2015, Failure of thrombolysis with streptokinase in acute myocardial infarction using ECG criteria: An observational study, *JK Science*, 17(3).
- Hartopo, A. B., Setianto, B. Y. and Taufiq, N., 2016, Pengaruh kadar soluble ST2 serum terhadap risiko kejadian kardiovaskular mayor selama perawatan intensif pada infark miokard akut dengan elevasi segmen-ST, *Tesis*, Fakultas Kedokteran Universitas Gadjah Mada, Program Pendidikan Dokter Spesialis Ilmu Penyakit Jantung dan Pembuluh Darah.
- Hartopo, A.B., Sukmasari, I., Puspitawati, I., 2018. The Utility of Point of Care Test for Soluble ST2 in Predicting Adverse Cardiac Events during Acute Care of ST-Segment Elevation Myocardial Infarction. *Cardiol. Res. Pract.* 2018, 3048941
- Ho, J. E., Sritara P, Defilippi C R., Wang T J., 2015, Soluble ST2 testing in the general population, *American Journal of Cardiology*. 115(7),22b-5b.

Irmalita, Juzar D A., Andrianto,Setianto B Y., Tobing D PL., Firman D, Firdaus, Isman, 2015, Pedoman Tatalaksana Sindrom Koroner Akut Edisi III. Jakarta :Centra Communications.

Kasper, D., Fauci, A., Hauser, S., Longo, D., Jameson, J., Loscalzo, J. And Harrison, T. (2015). *Harrison's principles of internal medicine*. 1st ed. New York: McGraw Hill Education.

Kocas C, Abaci O, Halil GS, Arslan S, Cetinkal G, Bostan C., 2015, Admission Hyperglycemia Is Associated with Failed Reperfusion Following Fibrinolytic Therapy in Patients with STEMI: Results of a Retrospective Study. *Am J Cardiovasc Drugs*, 15(1), p35-42.

Kumar V., Abbas A., Aster J C, 2012, *Robbins & Cotran Pathologic basis of disease*, 9th ed, Elsevier.

Lee YY, Tee MH, Zurkurnai Y, Than W, Sapawi M, Suhairi I., 2008, Thrombolytic failure with streptokinase in acute myocardial infarction using electrocardiogram criteria, *Singapore Med J*, 49(4),p304-310.

Liu, X., Hu Y., Huang W., Zhang G., Cao S., Yan X., Li L., Zhang L., Zheng X., 2018, Soluble ST2 for Prediction of Clinical Outcomes in Patients with ST-Segment Elevation Myocardial Infarction Receiving Primary PCI, *International Heart Journal*,60(1),19-26.

Mahendra, S. (2016) Prediksi Kegagalan Fibrinolitik dengan Menggunakan Sistem Skoring pada Pasien Infark Miokard Akut Elevasi Segmen ST. *Tesis*. Fakultas Kedokteran Universitas Gadjah Mada.

Mann, D. L., Zipes D P., Libby P., Bonow R O., 2014, *Braunwald's Heart Disease E-Book: A Textbook of Cardiovascular Medicine*. Elsevier Health Sciences.

Miller, A. M. dan Liew, F. Y., 2011, The IL-33/ST2 pathway - A new therapeutic target in cardiovascular disease, *Pharmacology and Therapeutics*, 131(2),179-186.

Miller, A. M., Xu D, Asquith DL, Denby L, Li Y, Sattar N, Baker AH, McInnes IB, Liew FY., 2012, IL-33 reduces the development of atherosclerosis, *The Journal of Experimental Medicine*, 205(2), 339 – 346.

O’Gara, P.T., Kushner, F.G., Ascheim, D.D., Casey, D.E., Chung, M.K., de Lemos, J.A., *et al.*, 2013. 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *Circulation* 127, e362–e425.

- Pascual-Figal, D. A. dan Januzzi, J. L., 2015, The biology of ST2: The international ST2 consensus panel, *American Journal of Cardiology*, 115(7), 3B-7B.
- Rhee, J.-W., Sabatine, M. S. and Lilly, L. S., 2011, *Ischemic Heart Disease*, in Lilly, L. S. (ed.) *Pathophysiology of Heart Disease 5th Edition*. 5th edn. Philadelphia: Lippincott Williams & Wilkins, pp. 135–160.
- Riley, Lyrad K. dan Rupert Jedda, 2015, Evaluation of Patients with Leukocytosis, *Am Fam Physician*, 92(11), p1004-1011.
- Ronad, G., Dixit, R., 2015, Factors Influencing the Outcome of Thrombolysis in Acute Myocardial Infarction. *Indian Journal of Basic and Applied Medical Research*, 4(3), pp.545-555.
- Sabatine, M.S., Morrow, D.A., Higgins, L.J., MacGillivray, C., Guo, W., Bode, C., et al., 2008. Complementary roles for biomarkers of biomechanical strain ST2 and N-terminal prohormone B-type natriuretic peptide in patients with ST-elevation myocardial infarction. *Circulation* 117, 1936–1944.
- Sakamoto T, Ogawa H, Kawano H, Hirai N, Miyamoto S, Takazoe K, Soejima H, Kugiyama K, Yoshimura M, Yasue H., 2000, Rapid change of platelet aggregability in acute hyperglycemia: detection by a novel laser-light scattering method. *Thromb Haemost.*83, p475–479.
- Sanada, S., Hakuno D, Higgins LJ, Schreiter ER, McKenzie AN, Lee RT., 2007, IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system, *Journal of Clinical Investigation*, 117(6), 1538-1549.
- Seki, K., Sanada S, Kudinova AY, Steinhauser ML, Handa V, Gannon J, Lee RT., 2009, Interleukin-33 prevents apoptosis and improves survival after experimental myocardial infarction through ST2 signaling, *Circulation: Heart Failure*, 2(6),684-691.
- Shah, A. M., Pfeffer MA, Hartley LH, Moyé LA, Gersh BJ, Rutherford JD, Lamas GA, Rouleau JL, Braunwald E, Solomon SD., 2010, Risk of All-Cause Mortality, Recurrent Myocardial Infarction, and Heart Failure Hospitalization Associated With Smoking Status Following Myocardial Infarction With Left Ventricular Dysfunction, *The American Journal of Cardiology*, 106(7), pp. 911–916.
- Shimpo, M., Morrow, D.A., Weinberg, E.O., Sabatine, M.S., Murphy, S.A., Antman, E.M., et al., 2004. Serum Levels of the Interleukin-1 Receptor Family Member ST2 Predict Mortality and Clinical Outcome in Acute Myocardial Infarction. *Circulation* 109, 2186–2190.

- Steg PG, James SK, Atar D, Badano LP, Blömstrom-Lundqvist C, Borger MA, Di Mario C, Dickstein K, Ducrocq G, Fernandez-Aviles F, Gershlick AH, Giannuzzi P, 2012, ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation, *European Heart Journal*, 33(20), 2569-2619.
- Strom, J. B. and Libby, P., 2011, *Atherosclerosis*, in Lilly, L. S. (ed.) *Pathophysiology of Heart Disease 5th Edition*. 5th edn. Philadelphia: Lippincott Williams & Wilkins, pp. 113–134.
- Sudoyo, A. W., Setiyohadi B., Alwi I, Macellus S., Setiati S., 2014, *Buku Ajar Ilmu Penyakit Dalam Edisi VI*, Jakarta: Interna Publishing pp. 1741-1754.
- Thygesen, K., Alpert, J., Jaffe, A., Simoons, M., Chaitman, B. and White, H., 2012, Third Universal Definition of Myocardial Infarction. *Circulation*, 126(16), pp.2020-2035.
- Kumar, V., Cotran, R.S., & Robbins, S.L., 2004. *Buku ajar patologi Robbins, Edisi 7*. Jakarta: EGC.
- Weinberg E.O, 2009, Supression of tumorigenecity 2 protein in heart disease: From discovery to mechanisms and prognostic value, *Biomark Med*, 3:495-511
- Welsh, R. C., Van de Werf F, Westerhout CM, Goldstein P, Gershlick AH, Wilcox RG, Danays T, Bluhmki E, Lopes RD, Steg PG, 2014, Outcomes of a pharmacoinvasive strategy for successful versus failed fibrinolysis and primary percutaneous intervention in acute myocardial infarction (from the strategic reperfusion early after myocardial infarction [STREAM] study), *American Journal of Cardiology*, 114(6), p811-p819.
- World Health Organization, 2018, *Noncommunicable Diseases Country Profiles 2018*, Switzerland: World Health Organization, pp.10.
- World Health Organization,2011, *Haemoglobin concentrations for the diagnosis of anaemia and assessment of severity, Vitamin and Mineral Nutrition Information System*. Geneva. World Health Organization.
- Willerson, J. T., Cohn, J N, Wellens H J J, Holmes D R., 2007, *Cardiovascular Medicine*. Springer :London.
- Wong, C. K., French JK, Gao W, White HD., 2002, Relation of initial platelet counts to Thrombolysis In Myocardial Infarction-3 flow rates at 90 minutes after commencing fibrinolytic therapy in patients with acute myocardial infarction, *American Journal of Cardiology*, 90(1), p54-p57.

Wong, N. D., 2014, Epidemiological studies of CHD and the evolution of preventive cardiology, *Nature Reviews Cardiology*, 11(5), p276-289.

Yaşar, A. S. Bilen E, Yüksel IO, Arslantaş U, Karakaş F, Kirbaş O, Bilge M., 2010, Association between admission mean platelet volume and coronary patency after thrombolytic therapy for acute myocardial infarction, *Türk Kardiyoloji Dernegi Arsivi*, 38(2),p85-p89.